Loading data for ERAS — first visit, this takes a few seconds.

Erasca, Inc. (ERAS)

NasdaqGS: ERAS · 即時價格 · USD

18.03

-1.46 (-7.49%)

收盤價： Sep 01, 2026, 6:53 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	13.86
市值	5.92B
營收 (ttm)	n/a
淨利（ttm）	-287M
	0.65
	-0.95
	n/a
	-28.36
P/B (ttm)	14.63
P/S (ttm)	0.00
財報日期	Nov 11, 2026

賣價	23.47
成交量	2,887,317
20 日平均成交量	4,813,958
開盤價	19.25
前收盤價	19.49
當日區間	18.00 - 19.59
52 週範圍	1.33 - 24.28
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 ERAS

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Jul 16, 2021

員工 103

證券交易所 NasdaqGS

股票代號 ERAS

網站 https://www.erasca.com

完整的公司簡介

財務表現

Erasca 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -124.55M，較前期減少 -22.95%。

財務報表

財報驚奇

Erasca 已於 Aug 11, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.14 低於預期 -0.03, 年增 -16.67% 下滑.

下次財報發布

Erasca, Inc. 的下次財報預計於 Nov 11, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

1 月前 · Simply Wall St.

Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this...

1 月前 · Simply Wall St.

Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a ...

1 月前 · Simply Wall St.

Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers

Erasca recently reported updated preliminary Phase 1 data for its oral pan-RAS molecular glue ERAS-0015, showing encouraging responses and a generally well-tolerated safety profile in RAS-mutant solid...

1 月前 · Insider Monkey

Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, stre...

2 月前 · Barrons.com

Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List

Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities’ top picks for the month.

第 1 頁，共 2 頁

Erasca, Inc. (ERAS)

Erasca, Inc.（ERAS）股價、分析與資料

關於 ERAS

財務表現

財報驚奇

下次財報發布

價格為何變動

新聞動態

1 月前 · Simply Wall St.

1 月前 · Simply Wall St.

1 月前 · Simply Wall St.

1 月前 · Insider Monkey

2 月前 · Barrons.com